ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMGastos comerciales, generales y administrativos101.51 M99.32 M107.56 M130.73 M116.21 M453.81 MInvestigación y desarrollo35.33 M36.31 M45.49 M48.02 M47.48 M177.31 MBeneficio operativo113.87 M102.07 M87.97 M43.62 M77.18 M310.83 MTotal de ingresos no operativos8.9 M14.05 M6.55 M2.29 M7.43 M30.32 MGastos por intereses, netos de intereses capitalizados5.04 M4.8 M4.92 M4.95 M5.08 M19.75 MIngresos no operativos, una vez deducidos los gastos por intereses-5.59 M-4.88 M-5.26 M-5.22 M-5.39 M-20.75 MIngresos/gastos extraordinarios9.45 M14.13 M6.89 M2.56 M7.75 M31.33 MBeneficio antes de impuestos-783 K96.53 M104.52 M42.38 M70.36 M313.79 MParticipación en los beneficios——————Impuestos11.01 M23.58 M25.76 M14.61 M16.28 M80.23 MParticipación minoritaria——————Otros ingresos/gastos después de impuestos-5.02 M-822 K-2.44 M-2.26 M348 K-5.17 MBeneficio neto antes de actividades interrumpidas-11.79 M72.94 M78.75 M27.77 M54.09 M233.56 MOperaciones suspendidas——————Beneficio neto-11.79 M72.94 M78.75 M27.77 M54.09 M233.56 MAjuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas-11.79 M72.94 M78.75 M27.77 M54.09 M233.56 MBeneficio básico por acción-0.171.061.150.410.843.46Beneficio por acción diluido-0.181.021.120.410.863.41Número medio de acciones ordinarias69.2 M68.67 M68.52 M67.23 M67.49 M271.91 MAcciones diluidas71.65 M71.46 M70.31 M67.66 M68.44 M277.88 MEBITDA105.12 M103.06 M88.83 M44.36 M65.7 M301.96 MEBIT60.24 M93.94 M79.72 M28.64 M17.49 M219.8 MCosto de los ingresos142.56 M135.06 M137.03 M161.65 M165.91 M599.66 MOtros costes de producción-1.64 M-1.38 M2.31 M1.93 M-667 K2.2 MAmortización y depreciación (flujo de caja)44.88 M9.12 M9.12 M15.71 M48.21 M82.16 M
Lantheus Holdings Inc
Lantheus, headquartered in Billerica, Massachusetts, is a company in the radiopharmaceuticals business. It has strategic partnerships with Bayer, Novartis, Regeneron as well as GE Healthcare and Siemens Healthineers.
Lantheus Holding, which became a NASDAQ company in 2015, is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB. Lantheus has offices in Massachusetts, New Jersey, Canada and Sweden.
Brian Markison has served as the company's CEO since March 1, 2024, following the retirement of Mary Anne Heino, who had led Lantheus for the preceding decade.